by | Apr 29, 2024 | Publications
Mol Biol Rep. 2024 Apr 29;51(1):587. doi: 10.1007/s11033-024-09517-2. ABSTRACT BACKGROUND: Patients with multiple myeloma exhibit malignant osteolytic bone disease due to excessive osteoclast formation and function. We recently identified that osteoclastogenic...
by | Apr 29, 2024 | Publications
Clin Exp Med. 2024 Apr 29;24(1):90. doi: 10.1007/s10238-024-01347-7. ABSTRACT Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the rapid proliferation of malignant plasma cells within the bone marrow. Standard therapies often fail due to...
by | Apr 28, 2024 | Publications
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461. ABSTRACT The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss, renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of malignant PCs within the...
by | Apr 28, 2024 | Publications
J Pers Med. 2024 Mar 29;14(4):360. doi: 10.3390/jpm14040360. ABSTRACT The benefit of associating anti-CD38 monoclonal antibodies to proteasome inhibitor (PI)/immunomodulatory agent (IA) and dexamethasone in the treatment of patients with relapsed or refractory...
by | Apr 28, 2024 | Publications
Curr Oncol Rep. 2024 Apr 27. doi: 10.1007/s11912-024-01537-2. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role...
by | Apr 28, 2024 | Publications
J Thromb Thrombolysis. 2024 Apr 27. doi: 10.1007/s11239-024-02977-0. Online ahead of print. ABSTRACT Patients diagnosed with lymphoma or multiple myeloma are at elevated risk of venous thromboembolism (VTE). Optimum risk stratification and effective thromboprophylaxis...
